New Market Study Published: Israel Pharmaceuticals & Healthcare Report Q3 2010

July 4, 2010 - PRLog -- BMI expects the total pharmaceutical market in Israel to increase in value from ILS6.14bn (US$1.56bn) in 2009 to ILS6.52bn (US$1.84bn) by 2014, at a compound annual growth rate (CAGR) of 3.2% in US dollar terms. Per-capita spending on medicines will increase from US$211 in 2009 to US$227 by 2014, By this time, 0.65% of GDP will be spent on pharmaceuticals, which highlights a marginal decline since 2009.

Generic drug spending in Israel was ILS1.38bn (US$352mn) in 2009, accounting for just over a fifth of all pharmaceutical expenditure. In line with our emerging market trends, BMI believes the generic drug sector holds much potential for higher sales. The 2011 patent cliff should cause a global increase in generic drug sales by volume and we expect a massive uptake in demand. This will be no less the case in Israel and BMI expects expenditure on the country's generic drug segment to continue to increase as a percentage of the total pharmaceutical expenditure.

Conversely, patented drugs are expected to decline proportionally from 54.6% o f the total drug market in Israel to 44.8%. The slow drop can be largely attributed to prescribing patterns and brand loyalty, particularly for patients on existing chronic treatments. While the Israeli government has established a US$250mn biotechnology fund to rejuvenate the innovative drug development sector, the local drugmaking sector is still in need of investment.

Teva Pharmaceutical Industries has successfully developed and marketed its own patented medicines, but smaller, research-based ventures which have developed innovative drugs have had to use multinationals as commercial partners owing to their lack of marketing experience. Biotechnology is a rapidly emerging segment of the pharmaceutical sector which is more expensive, but therefore higher value. Although Teva will continue to focus its core efforts on generic drug production, it will also invest more heavily in high-value research and development (R&D). For Israel, biotechnology sector development can provide a means of boosting patented drug spending, although only in the long run.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/71555_israel_pharmaceuticals_h...

Report Table of Contents:

Executive Summary
SWOT Analysis
- Israel Pharmaceuticals And Healthcare Industry SWOT
- Israel Political SWOT
- Israel Economics SWOT
- Israel Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East and Africa - Regional Pharmaceuticals Business Environment Ratings For Q310
- Limits to Potential Returns
- Risks to Realisation of Returns
Israel - Market Summary
Regulatory Regime
- Intellectual Property
- Recent IP Developments
- Shortcomings of the IP Environment
- Counterfeit Drugs
- Pricing System
- Price Cuts
- Reimbursement System
- Recent Reimbursement Developments
- Funding For Reimbursement
Industry Trends and Developments
- Epidemiology
- Healthcare Sector
- Healthcare Insurance
- Recent Healthcare Coverage Developments
- Healthcare Financing
- Retail Pharmacy Sector
- Research and Development Sector
- Table: Israel's R&D Law - Conditions For OCS Funding
- Biotechnology
- Recent Biotechnology Developments
- International Research and Development Co-operation
- Private Sector
- Medical Device Industry
- Recent Medical Device Company Developments
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Israel - Economic Activity
- Prescription Market Forecast
- Patented Market Forecast
- Generic Drug Market Forecast
- OTC Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Recent Pharmaceutical Industry Developments
Company Profiles
- Indigenous Manufacturer Profiles
- Teva Pharmaceutical Industries
- Taro
- Perrigo (Agis Industries)
- Dexcel
- Trima
- Rekah
- Multinationals
- Pfizer
- GlaxoSmithKline
- Novartis
- Sanofi-Aventis
- Merck & Co
Country Snapshot: Israel Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.